Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  arsenic trioxide
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-16 of 16 for your search:
Start Over
Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 30052004, NCT00196768
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: APL2012, NCT01987297
Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: IAPLSG2004, BT/PR4460/Med/14/531/2003, NCT00517712
Acute Promyelocytic Leukemia 2006 (APL)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P050604, NCT00378365
A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: Under 16
Sponsor: Other
Protocol IDs: 2010001, NCT02200978
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 12 to 21
Sponsor: NCI, Other
Protocol IDs: AAML1331, NCI-2014-02266, U10CA180886, NCT02339740
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-040, NCT01404949
Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin
Phase: Phase II
Type: Treatment
Status: Active
Age: 10 and over
Sponsor: Other
Protocol IDs: 2010-0981, NCI-2011-02767, NCT01409161
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: HEMAML0023, NCI-2013-00767, 26938, NCT01835288
Proteasome Inhibition in Acute Promyelocytic Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 75
Sponsor: Other
Protocol IDs: IRB 8225 27/02/13, NCT01950611
Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2012AA022701, NCT02018757
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 11-107, NCT01397734
Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV55, NCT02066870
Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
Phase: No phase specified
Type: Treatment
Status: Active
Age: 1 to 16
Sponsor: Other
Protocol IDs: CCAPL2010, NCT01191541
Start Over